Skip to Content

How does Besponsa work to treat acute lymphoblastic leukemia (ALL)?

Medically reviewed by Last updated on Sep 30, 2020.

Official Answer


Besponsa works by binding to B-cell ALL cancer cells that express the CD22 antigen and blocking the growth of cancerous cells.

Besponsa (inotuzumab ozogamicin), from Pfizer, is a CD22 monoclonal antibody and calicheamicin cytotoxic agent conjugate for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) in adults.

Related Medical Questions

Drug Information

Related Support Groups